NCT06499350 - A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

September 1, 2026

Conditions

Advanced Malignant Solid Tumors

Interventions

DRUG

FC084CSA+Tislelizumab combination (dose escalation)

Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy

DRUG

RP2D of FC084CSA+Tislelizumab combination (dose expansion)

RP2D of FC084CSA+fixed dose Tislelizumab combination therapy

Trial Locations (1)

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

FindCure Biosciences (ZhongShan) Co., Ltd.

INDUSTRY